[Skip to Content]

Upstate Active Clinical Trials

Study Title:

EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy
alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced
Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature driven Analysis

What is the purpose of the study?

This phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and pemetrexed maintenance in treating patients with stage IV non-squamous non-small cell lung cancer.

Upstate Institutional Review Board (IRB) Number:

1421585

Study/Protocol ID:

EA5163

Study Phase:

III

Patient Age Group:

Adults

Principal Investigator:

Stephen L Graziano, MD

ClinicalTrials.Gov ID:

NCT03793179

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Nicole D Bunyea
Phone: 315-464-8276
Email: bunyean@upstate.edu

Return to Previous Page || Search Again

Top